Viewing Study NCT01824992


Ignite Creation Date: 2025-12-24 @ 3:49 PM
Ignite Modification Date: 2025-12-29 @ 5:44 PM
Study NCT ID: NCT01824992
Status: COMPLETED
Last Update Posted: 2013-04-05
First Post: 2013-03-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
Sponsor: Lee's Pharmaceutical Limited
Organization:

Study Overview

Official Title: a Multi-sites, Randomized, Parallel, Controlled Clinical Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection
Status: COMPLETED
Status Verified Date: 2013-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type infections and clinical negative conversion.

285 patients with positive high risk HPV infection were randomized into interferon gel group and control group at ratio of 2:1 (203 patients in treatment group and 82 patients in control group). The patients in treatment group received 1g recombinant human α-2b interferon gel every other day for consecutive 3 courses of treatment, whereas no treatment was conducted in control group.
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
China State FDA OTHER China State Food and Drug Administration View